文献速递胸部肿瘤

放化疗对不可切除局部晚期NSCLC免疫微环境的影响及后续抗PD-(L)1治疗的疗效

Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2020-10-08

该回顾性研究纳入422例接受放化疗的不可切除局部晚期NSCLC患者,其中65例放化疗失败后接受抗PD-(L)1治疗,客观缓解率48%,无进展生存期8.7个月(95%CI 4.5-13),且疗效与放化疗前PD-L1表达水平无关;放化疗后瘤内CD8阳性TIL密度显著增加(中位110/mm2 vs 470/mm2,p=0.025)。

要点

  • 放化疗失败后抗PD-(L)1治疗的ORR为48%,PFS为8.7个月(95%CI 4.5-13)。
  • 抗PD-(L)1疗效与放化疗前PD-L1表达水平无关。
  • 放化疗后瘤内CD8阳性TIL密度显著增加(p=0.025)。

核心结论

  • 放化疗失败后的局部晚期NSCLC患者接受抗PD-(L)1治疗有效,且不受放化疗前PD-L1表达影响。
  • 该疗效优于晚期NSCLC标准二线治疗的历史数据。

研究设计与样本

  • 回顾性分析2007至2018年接受放化疗的不可切除局部晚期NSCLC患者,共422例。
  • 其中65例放化疗失败后接受抗PD-(L)1治疗,评估疗效。
  • 采用配对FFPE标本比较放化疗前后PD-L1(22C3)表达及CD8阳性TIL的分布。

主要发现

  • 抗PD-(L)1治疗的客观缓解率为48%,无进展生存期为8.7个月(95%CI 4.5-13)。
  • 缓解率和PFS与放化疗前PD-L1表达水平无关。
  • 18例配对标本中16例PD-L1表达发生变化,但无特定趋势(升高9例,降低7例,不变2例)。
  • 放化疗后瘤内CD8阳性TIL密度较前显著增加(中位110/mm2 vs 470/mm2,p=0.025)。

临床怎么用

  • 对于放化疗后进展的不可切除局部晚期NSCLC,可考虑抗PD-(L)1治疗,无需依据放化疗前PD-L1表达筛选。
  • 放化疗后瘤内CD8阳性TIL密度增加提示免疫微环境改变,可能增强后续免疫治疗疗效。

局限性

  • 回顾性研究设计。
  • 接受抗PD-(L)1治疗的患者样本量较小(65例)。
  • PD-L1表达变化的配对标本仅18例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A history of radiotherapy and chemoradiotherapy (CRT) reportedly increases the efficacy of the PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC). We investigated the efficacy of anti-PD-(L)1 therapy after CRT failure and how CRT changes the status of PD-L1 expression on tumours and on tumour-infiltrated lymphocytes (TILs). METHODS: We retrospectively reviewed patients with unresectable locally advanced NSCLC (LA-NSCLC) who were treated with CRT between 2007 and 2018 and evaluated the efficacy of the PD-(L)1 blockade after CRT failure. We also compared the PD-L1 (clone: 22C3) expression levels and the tumoral and stromal distributions of CD8-positive TILs using paired formalin-fixed, paraffin-embedded specimens obtained before and after CRT. RESULTS: We identified 422 patients and 65 patients who had relapsed after CRT received anti-PD-(L)1 therapy. The objective response rate (ORR) and the progression-free survival (PFS) after anti-PD-(L)1 therapy were 48% and 8.7 months (95% CI, 4.5-13), respectively. The RR and PFS did not differ according to the pre-CRT PD-L1 expression levels. PD-L1 expression changed in 16 of the 18 patients between before and after CRT, but a specific trend was not seen (increased, 9 patients; decreased, 7 patients; no change, 2 patients). In contrast, the density of tumoral CD8-positive TILs increased after CRT treatment (pre-CRT median, 110/mm2 versus post-CRT median, 470/mm2; p = 0.025). CONCLUSIONS: Anti-PD-(L)1 therapy was effective in patients with LA-NSCLC who had progressed after CRT regardless of their pre-CRT PD-L1 expression. The efficacy of anti-PD-(L)1 therapy for patients with NSCLC with CRT failure was superior to that of standard second-line treatment for patients with advanced NSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Shirasawa M, Yoshida T, Matsumoto Y, et al. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. Eur J Cancer. 2020. PMID: 33039811. doi:10.1016/j.ejca.2020.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。